187 related articles for article (PubMed ID: 31196964)
1. Diagnostic value of RASSF1A methylation for breast cancer: a meta-analysis.
Li M; Wang C; Yu B; Zhang X; Shi F; Liu X
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31196964
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Capacity of RASSF1A Promoter Methylation as a Biomarker in Tissue, Brushing, and Blood Samples of Nasopharyngeal Carcinoma.
Ye M; Huang T; Ni C; Yang P; Chen S
EBioMedicine; 2017 Apr; 18():32-40. PubMed ID: 28396012
[TBL] [Abstract][Full Text] [Related]
3. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of RASSF1A hypermethylation in colorectal cancer: a meta-analysis.
Hu H; Zhou C; Li B; Chen Y; Dai J; Mao Y; Huang T; Yu H; Chen M; Zhao J; Duan S
Pathol Res Pract; 2018 Oct; 214(10):1572-1578. PubMed ID: 30082160
[TBL] [Abstract][Full Text] [Related]
5. Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection.
Dong X; He H; Zhang W; Yu D; Wang X; Chen Y
Diagn Pathol; 2015 Aug; 10():133. PubMed ID: 26238200
[TBL] [Abstract][Full Text] [Related]
6. Correlation Between RASSF1A Gene Promoter Hypermethylation in Serum or Sputum and Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis.
Zhang Z; Yan S; Cui H; Chen H; Liu J
Med Sci Monit; 2019 Jul; 25():5518-5524. PubMed ID: 31342946
[TBL] [Abstract][Full Text] [Related]
7. Association between Ras association domain family 1A promoter methylation and hepatocellular carcinoma: a meta-analysis.
Zhao ZH; Fan YC; Yang Y; Wang K
World J Gastroenterol; 2013 Nov; 19(41):7189-96. PubMed ID: 24222965
[TBL] [Abstract][Full Text] [Related]
8. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients.
Shukla S; Mirza S; Sharma G; Parshad R; Gupta SD; Ralhan R
Epigenetics; 2006; 1(2):88-93. PubMed ID: 17998817
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation patterns of RAR-β2 and RASSF1A gene promoters in FNAB samples from Greek population with benign or malignant breast lesions.
Kougioumtsidou N; Vavoulidis E; Nasioutziki M; Symeonidou M; Pratilas GC; Mareti E; Petousis S; Chatzikyriakidou A; Grimbizis G; Theodoridis T; Miliaras D; Dinas K; Zepiridis L
Diagn Cytopathol; 2021 Jan; 49(1):153-164. PubMed ID: 32530576
[TBL] [Abstract][Full Text] [Related]
10. Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis.
Si JG; Su YY; Han YH; Chen RH
Genet Test Mol Biomarkers; 2014 Jun; 18(6):394-402. PubMed ID: 24665911
[TBL] [Abstract][Full Text] [Related]
11. CircRNAs as promising biomarker in diagnosis of breast cancer: An updated meta-analysis.
Chu M; Fang Y; Jin Y
J Clin Lab Anal; 2021 Sep; 35(9):e23934. PubMed ID: 34331339
[TBL] [Abstract][Full Text] [Related]
12. Long Noncoding RNA Serve as a Potential Predictive Biomarker for Breast Cancer: A Meta-Analysis.
Jiang X; Zhang G; Wu J; Lin S; Liu Y; Ma Y; Ma M
Biomed Res Int; 2020; 2020():9045786. PubMed ID: 32462032
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of RASSF1A methylation status in non-small cell lung cancer (NSCLC) patients: A meta-analysis of prospective studies.
Hu H; Zhou Y; Zhang M; Ding R
Biomarkers; 2019 May; 24(3):207-216. PubMed ID: 30764677
[No Abstract] [Full Text] [Related]
14. Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis.
Li S; Yang X; Yang J; Zhen J; Zhang D
Clin Exp Med; 2016 Feb; 16(1):29-35. PubMed ID: 25516467
[TBL] [Abstract][Full Text] [Related]
15. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer.
Papadopoulou E; Davilas E; Sotiriou V; Georgakopoulos E; Georgakopoulou S; Koliopanos A; Aggelakis F; Dardoufas K; Agnanti NJ; Karydas I; Nasioulas G
Ann N Y Acad Sci; 2006 Sep; 1075():235-43. PubMed ID: 17108217
[TBL] [Abstract][Full Text] [Related]
16. Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis.
Pan J; Chen J; Zhang B; Chen X; Huang B; Zhuang J; Mo C; Qiu S
PLoS One; 2013; 8(9):e75283. PubMed ID: 24073258
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of the
Lao TD; Thieu HH; Nguyen DH; Le TAH
Int J Biol Markers; 2022 Mar; 37(1):31-39. PubMed ID: 34935528
[TBL] [Abstract][Full Text] [Related]
18. Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis.
Ye M; Huang T; Ying Y; Li J; Yang P; Ni C; Zhou C; Chen S
Oncotarget; 2017 Feb; 8(6):9230-9242. PubMed ID: 27999208
[TBL] [Abstract][Full Text] [Related]
19. Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer.
Kristiansen S; Nielsen D; Sölétormos G
Clin Epigenetics; 2016; 8():35. PubMed ID: 27042241
[TBL] [Abstract][Full Text] [Related]
20. Methylation status and protein expression of RASSF1A in breast cancer patients.
Hagrass HA; Pasha HF; Shaheen MA; Abdel Bary EH; Kassem R
Mol Biol Rep; 2014 Jan; 41(1):57-65. PubMed ID: 24253900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
